# Spatial transcriptomics uncovers pharmacokinetic and tumor-intrinsic determinants of resistance to trastuzumab deruxtecan in breast cancer

Source: [cell.com](https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00594-X?rss=yes) · 2026-11-20 · Medicine
Page: https://themorning.science/story/spatial-transcriptomics-uncovers-pharmacokinetic-and-tumor-intrinsic-determinant-444c92fda1f4ec8e
Kind: research · Impact: medium

## In brief

- Park et al. performed spatial transcriptomics in patients with metastatic breast cancer treated with trastuzumab deruxtecan.
- More spatially dispersed HER2 expression correlated with improved response.
- In HER2-low tumors, resistant tumor fragments showed increased pharmacokinetic barriers.

## Why it matters

The study points to spatial HER2 distribution and pharmacokinetic barriers as possible causes of resistance to a HER2-directed antibody-drug conjugate, which may inform patient selection and future drug design.

## Timeline

- 2026-11-20: Study on spatial transcriptomics and resistance to trastuzumab deruxtecan published in Cell Reports Medicine

## Coverage

- [Spatial transcriptomics uncovers pharmacokinetic and tumor-intrinsic determinants of resistance to trastuzumab deruxtecan in breast cancer](https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00594-X?rss=yes) — cell.com, 2026-11-20

Tags: breast cancer, spatial transcriptomics, drug resistance, her2, antibody-drug conjugate

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
